Stifel Nicolaus Reiterates “$130.00” Price Target for Celgene (CELG)

Stifel Nicolaus set a $130.00 target price on Celgene (NASDAQ:CELG) in a report published on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on CELG. Oppenheimer set a $166.00 price target on Celgene and gave the stock a buy rating in a research report on Monday. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the company a hold rating in a research report on Monday. Deutsche Bank set a $110.00 target price on Celgene and gave the company a hold rating in a research report on Monday. Mizuho set a $128.00 target price on Celgene and gave the company a buy rating in a research report on Friday, January 5th. Finally, Credit Suisse Group set a $123.00 target price on Celgene and gave the company a buy rating in a research report on Thursday, December 28th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have issued a buy rating to the company. Celgene presently has an average rating of Buy and an average price target of $131.18.

Celgene (NASDAQ:CELG) traded up $1.42 on Monday, hitting $106.00. The stock had a trading volume of 8,748,823 shares, compared to its average volume of 6,330,000. The company has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.58 EPS. research analysts forecast that Celgene will post 6.68 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. lifted its position in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI lifted its position in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares in the last quarter. Robecosam AG purchased a new position in shares of Celgene in the third quarter valued at approximately $114,000. Guidant Wealth Advisors purchased a new position in shares of Celgene in the third quarter valued at approximately $119,000. Finally, Capital Bank & Trust Co lifted its position in shares of Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 517 shares in the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.

WARNING: “Stifel Nicolaus Reiterates “$130.00” Price Target for Celgene (CELG)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.com-unik.info/2018/01/12/stifel-nicolaus-reiterates-130-00-price-target-for-celgene-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit